Elizabeth Fitzpatrick
Psychiatry · Omaha, NENPI 1528189206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 645 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 26.7% of the total. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sunovion Pharmaceuticals Inc.$1K
- Lundbeck LLC$924
- Takeda Pharmaceuticals U.S.A., Inc.$913
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$906
- Alkermes, Inc.$892
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$2002%
- Food & beverage$10,12998%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 196 | $2,758 |
| Sunovion Pharmaceuticals Inc. | 85 | $1,132 |
| Lundbeck LLC | 65 | $924 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $913 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $906 |
| Alkermes, Inc. | 46 | $892 |
| Otsuka America Pharmaceutical, Inc. | 52 | $891 |
| Vanda Pharmaceuticals Inc. | 23 | $472 |
| Teva Pharmaceuticals USA, Inc. | 15 | $214 |
| Teladoc Health, Inc. | 1 | $200 |
| Axsome Therapeutics, Inc. | 9 | $200 |
| Johnson & Johnson | 8 | $156 |
| Idorsia Pharmaceuticals US Inc | 7 | $118 |
| Corium, LLC | 6 | $112 |
| Neurocrine Biosciences, Inc. | 6 | $102 |
| Eisai Inc. | 4 | $62 |
| Avanir Pharmaceuticals, Inc. | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Almatica Pharma LLC | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Bausch Health US, LLC | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Noven Therapeutics, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$10,347 in reported general payments places this provider in the 90th percentile of 160 psychiatry providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $18,663 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,080 |
| Ziprasidone Hcl | 27 | $2,568 |
| Aripiprazole | 15 | $2,165 |
| Quetiapine Fumarate | 65 | $1,403 |
| Lamotrigine | 81 | $1,133 |
| Bupropion XlBupropion Hcl | 38 | $918 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $824 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $806 |
| Escitalopram Oxalate | 38 | $677 |
| Prazosin Hcl | 14 | $612 |
| Bupropion Hcl SrBupropion Hcl | 17 | $436 |
| Gabapentin | 36 | $436 |
| Lurasidone Hcl | 17 | $359 |
| Trazodone Hcl | 60 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $906 | $18,66312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $913 | $5,08014 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $21742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Omaha
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Syed SattarOmaha$16K
- Michael SedlacekOmaha$15K
- Sriram RamaswamyOmaha$13K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
- Michael EggerOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.